Novartis International AG has appointed Dr Vasant Narasimhan, currently global head (drug development) and chief medical officer as its new chief executive officer (CEO), effective from 1 February 2018.
He succeeds Joseph Jimenez, who has informed the board of directors of his desire to step down as CEO in 2018, after eight years in the position.
Narasimhan is a member of the executive committee and joined Novartis in 2005. He has held numerous leadership positions across Novartis in commercial, drug development and strategy roles. Prior to his current role, he served as head of development for Novartis Pharmaceuticals. Narasimhan is an elected member of the US National Academy of Medicine.
"I would like to express my sincere appreciation for Joe's achievements as CEO. We anticipate a smooth transition as Joe built a strong leadership team and mentored his successor. Novartis will be well positioned to continue its momentum," said Joerg Reinhardt, chairman of the Novartis board of directors.
Novartis International AG has appointed Dr Vasant Narasimhan, currently global head (drug development) and chief medical officer as its new chief executive officer (CEO), effective from 1 February 2018.
He succeeds Joseph Jimenez, who has informed the board of directors of his desire to step down as CEO in 2018, after eight years in the position.
Narasimhan is a member of the executive committee and joined Novartis in 2005. He has held numerous leadership positions across Novartis in commercial, drug development and strategy roles. Prior to his current role, he served as head of development for Novartis Pharmaceuticals. Narasimhan is an elected member of the US National Academy of Medicine.
"I would like to express my sincere appreciation for Joe's achievements as CEO. We anticipate a smooth transition as Joe built a strong leadership team and mentored his successor. Novartis will be well positioned to continue its momentum," said Joerg Reinhardt, chairman of the Novartis board of directors.
No comments:
Post a Comment